Wearable Health Solutions (WHSI) 10-Q 10 May 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2022	May 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	000-56368
Entity Registrant Name	WEARABLE HEALTH SOLUTIONS, INC.
Entity Central Index Key	0001443089
Entity Tax Identification Number	26-3534190
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2901 W. Coast Highway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92663
City Area Code	949
Local Phone Number	270-7460
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,493,142,608

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Current Assets
Cash and cash equivalents	$ 569,973	$ 847,430
Accounts receivable, net	0	25,694
Accounts receivable, other	2,000	2,000
Prepaid Inventory	16,197	22,682
Prepaid expenses	0	10,000
Total Current Assets	588,170	907,806
Property, Plant & Equipment
Dealer portal (net of $5,849 and $0 depreciation, as of March 31, 2022 and June 30, 2021, respectively)	44,151	0
Total Property, Plant & Equipment	44,151	0
Total Assets	632,321	907,806
LIABILITIES and SHAREHOLDERS' DEFICIT
COMMITMENTS AND CONTINGENCIES (Note 12)
Current liabilities
Accounts payable	107,268	331,876
Accrued expenses and other current liabilities	377,360	296,920
Accrued expenses - related party	320,101	579,673
Contract liabilities - Deferred revenue	82,306	108,298
Line of credit	397,500	397,500
Derivative liability	0	281,845
Notes payable	430,380	853,244
Note payable - other	50,000	50,000
Note payable - related party	47,000	425,000
Convertible notes - Leonite	0	260,000
Convertible notes- other	673,750	673,750
Total current liabilities	2,485,665	4,258,106
TOTAL LIABILITIES	2,485,665	4,258,106
Common stock
Common Stock: $0.0001 par value; 3,000,000,000 shares authorized,1,080,492,608 and 647,074,177 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively	108,049	64,708
Common stock to be issued (407,632,500 and 20,050,000 shares as of March 31, 2022 and June 30, 2021, respectively)	6,535,559	169,005
Additional paid in capital	29,967,450	22,732,295
Accumulated deficit	(38,465,530)	(26,374,227)
Total Shareholders’ Deficit	(1,853,344)	(3,350,300)
Total Liabilities and Shareholders’ Deficit	632,321	907,806
Series A Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	1	1
Series B Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	1	1
Series C Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	684	684
Series D Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	43	43
Series E Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	400	190
Preferred stock to be issued	$ 0	$ 57,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Depreciation	$ 5,849	$ 0
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred Stock to be issued	0	100,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,080,492,608	647,074,177
Common stock, shares outstanding	1,080,492,608	647,074,177
Common stock to be issued	407,632,500	20,050,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	100,000	100,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	688	688
Preferred stock, shares outstanding	688	688
Series B Preferred Stock [Member]
Preferred stock, shares authorized	62,500	62,500
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	9,938	9,938
Preferred stock, shares outstanding	9,938	9,938
Series C Preferred Stock [Member]
Preferred stock, shares authorized	6,944,445	6,944,445
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	6,838,889	138,886
Preferred stock, shares outstanding	6,838,889	138,886
Series D Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	425,000	425,000
Preferred stock, shares outstanding	425,000	425,000
Series E Preferred Stock [Member]
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	4,000,000	1,900,000
Preferred stock, shares outstanding	4,000,000	1,900,000

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenue
Gross Revenue	$ 212,982	$ 283,321	$ 819,601	$ 1,035,771
Cost of sales	(111,434)	(75,194)	(457,307)	(620,215)
Gross profit	101,548	208,127	362,294	415,556
Operating expenses
Selling expense	44,346	32,552	318,708	34,650
Depreciation	2,500	0	5,849	0
Research and development expense	209,800	0	374,484	0
Consulting and professional fees	106,624	50,554	462,998	158,513
Insurance	28,124	13,515	50,507	35,272
Rent	4,050	3,300	12,555	11,418
Salaries and wages	6,974,610	280,809	10,904,649	2,532,293
Software expense	24,500	10,512	22,887	13,506
General and administrative	89,084	24,835	295,659	89,998
Total Operating expenses	7,483,638	416,077	12,448,296	2,875,650
Loss from operations	(7,382,090)	(207,950)	(12,086,002)	(2,460,094)
Other income / (expense)
Other income	23,000	0	23,000	0
Gain on debt extinguishment			96,145
Gain on loan forgiveness	0	222,981	0	81,000
Change in fair value of derivative instrument	0	0	(213,053)	(31,940)
Gain on settlement of accounts payable	0	0	156,616	0
Interest expense	(8,493)	(28,069)	(68,009)	(121,001)
Total other income (expense)	14,507	194,912	(5,301)	(71,941)
Net loss before taxes	(7,367,583)	(13,038)	(12,091,303)	(2,532,035)
Income tax	0	0	0	0
Net loss	$ (7,367,583)	$ (13,038)	$ (12,091,303)	$ (2,532,035)
Net loss per common share - Basic and Diluted	$ (0.0073)	$ 0	$ (0.01487)	$ (0.00366)
Weighted average common shares outstanding - Basic & Diluted	1,008,459,767	557,529,809	813,299,239	692,481,701
Hardware Revenue [Member]
Revenue
Gross Revenue	$ 5,659	$ 90,412	$ 82,644	$ 296,426
Service Revenue [Member]
Revenue
Gross Revenue	$ 207,323	$ 192,909	$ 736,957	$ 739,345

Consolidated Statement of Share

Consolidated Statement of Shareholder's Deficit (unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series B [Member]	Preferred Stock Series C [Member]	Series C To Be Issued [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Series E To Be Issued [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
As at December 31, 2021 at Jun. 30, 2020	$ 1	$ 1	$ 14	$ 375,200	$ 43	$ 400	$ 650,000	$ 29,740	$ 71,415	$ 18,578,122	$ (3,356,285)
Beginning balance, shares at Jun. 30, 2020	688	9,938	138,886	6,700,003	425,000	4,000,000	1,000,000	297,399,177	10,350,000
Loss for the period
Issuance of Series C Preferred shares			$ 670	$ (375,200)						374,530
Issuance of Series C Preferred shares, shares			6,700,003	(6,700,003)
Return of preferred stock						$ (400)					(400)
Return of preferred stock, shares						(4,000,000)
Preferred stock issued/officer comp						$ 100	(80,000)			649,900	570,000
Preferred stock issued/officer comp , shares						1,000,000
Common stock issued/officer comp								$ 20,000	$ 1,500	1,120,000	1,141,500
Common stock issued/officer comp , shares								200,000,000	150,000
Loss for the period											(1,949,592)
As at March 31, 2022 at Sep. 30, 2020	$ 1	$ 1	$ 684		$ 43	$ 100	$ 570,000	$ 49,740	$ 72,915	20,722,552	(3,594,777)
Ending balance, shares at Sep. 30, 2020	688	9,938	6,838,889		425,000	1,000,000	1,000,000	497,399,177	10,500,000
As at December 31, 2021 at Jun. 30, 2020	$ 1	$ 1	$ 14	$ 375,200	$ 43	$ 400	$ 650,000	$ 29,740	$ 71,415	18,578,122	(3,356,285)
Beginning balance, shares at Jun. 30, 2020	688	9,938	138,886	6,700,003	425,000	4,000,000	1,000,000	297,399,177	10,350,000
Loss for the period												(2,532,035)
As at March 31, 2022 at Mar. 31, 2021	$ 1	$ 1	$ 684		$ 43	$ 100	$ 570,000	$ 55,789	$ 78,494	20,836,402	(4,051,743)
Ending balance, shares at Mar. 31, 2021	688	9,938	6,838,889		425,000	1,000,000	1,000,000	557,888,177	11,100,000
As at December 31, 2021 at Sep. 30, 2020	$ 1	$ 1	$ 684		$ 43	$ 100	$ 570,000	$ 49,740	$ 72,915	20,722,552	(3,594,777)
Beginning balance, shares at Sep. 30, 2020	688	9,938	6,838,889		425,000	1,000,000	1,000,000	497,399,177	10,500,000
Loss for the period
Preferred stock issued/officer comp									$ 985		985
Preferred stock issued/officer comp , shares									150,000
Common stock issued/officer comp
3a10 shares								$ 4,899			4,899
3a10 shares , shares								48,989,000
Common stock for officer comp									$ 1,376		1,376
Common stock for officer comp , shares									225,000
Loss for the period											(569,405)
As at March 31, 2022 at Dec. 31, 2020	$ 1	$ 1	$ 684		$ 43	$ 100	$ 570,000	$ 54,639	$ 75,276	20,722,552	(4,156,922)
Ending balance, shares at Dec. 31, 2020	688	9,938	6,838,889		425,000	1,000,000	1,000,000	546,388,177	10,875,000
Loss for the period												(13,038)
Preferred stock issued/officer comp											0
Common stock issued/officer comp
3a10 shares								$ 1,150		113,850	115,000
3a10 shares , shares								11,500,000
Common stock for officer comp									$ 3,218		3,218
Common stock for officer comp , shares									225,000
Loss for the period											(13,038)
As at March 31, 2022 at Mar. 31, 2021	$ 1	$ 1	$ 684		$ 43	$ 100	$ 570,000	$ 55,789	$ 78,494	20,836,402	(4,051,743)
Ending balance, shares at Mar. 31, 2021	688	9,938	6,838,889		425,000	1,000,000	1,000,000	557,888,177	11,100,000
As at December 31, 2021 at Jun. 30, 2021	$ 1	$ 1	$ 684		$ 43	$ 190	$ 57,000	$ 64,708	$ 169,005	22,732,295	(3,350,300)	(3,350,300)
Beginning balance, shares at Jun. 30, 2021	688	9,938	6,838,889		425,000	1,900,000	100,000	647,074,177	20,050,000
Loss for the period
Common stock for officer comp									$ 2,498		2,498
Common stock for officer comp , shares									225,000
Common stock for comp								$ 700	$ 60,000	74,300	135,000
Common stock for comp , shares								7,000,000	5,000,000
Common stock for debt conversion								$ 2,527		250,166	252,693
Common stock for debt conversion , shares								25,269,253
Preferred stock for compensation						200				2,999,800	3,000,000
Preferred stock for compensation, shares						2,000,000
Issuance of issuable shares								$ 23,250	$ (100,000)	2,301,750	2,225,000
Shares sold for cash , shares								232,500,000	(10,000,000)
Loss for the period											(4,354,735)
As at March 31, 2022 at Sep. 30, 2021	$ 1	$ 1	$ 684		$ 43	$ 390	$ 57,000	$ 91,185	$ 131,503	28,358,311	(2,089,845)
Ending balance, shares at Sep. 30, 2021	688	9,938	6,838,889		425,000	3,900,000	100,000	911,843,430	15,275,000
As at December 31, 2021 at Jun. 30, 2021	$ 1	$ 1	$ 684		$ 43	$ 190	$ 57,000	$ 64,708	$ 169,005	22,732,295	(3,350,300)	(3,350,300)
Beginning balance, shares at Jun. 30, 2021	688	9,938	6,838,889		425,000	1,900,000	100,000	647,074,177	20,050,000
Loss for the period												(12,091,303)
As at March 31, 2022 at Mar. 31, 2022	$ 1	$ 1	$ 684		$ 43	$ 400		$ 108,049	$ 6,535,559	29,967,450	(1,853,343)	(1,853,344)
Ending balance, shares at Mar. 31, 2022	688	9,938	6,838,889		425,000	4,000,000	0	1,080,492,608	407,632,500
As at December 31, 2021 at Sep. 30, 2021	$ 1	$ 1	$ 684		$ 43	$ 390	$ 57,000	$ 91,185	$ 131,503	28,358,311	(2,089,845)
Beginning balance, shares at Sep. 30, 2021	688	9,938	6,838,889		425,000	3,900,000	100,000	911,843,430	15,275,000
Loss for the period
Common stock for comp									$ 2,422		2,422
Common stock for comp , shares									225,000
Common stock for debt conversion								$ 4,114		420,900	425,014
Common stock for debt conversion , shares								41,149,178
Preferred stock for compensation						10	(57,000)			56,990
Preferred stock for compensation, shares						100,000	(100,000)
Subscriptions receivable										(100,000)	(100,000)
Issuance of issuable shares								$ 9,750	$ 200,000	965,250	1,175,000
Shares sold for cash , shares								97,500,000	20,000,000
Common stock for services								$ 1,000	$ (69,000)	68,000
Common stock for services , shares								10,000,000	(10,000,000)
Loss for the period											(368,985)
As at March 31, 2022 at Dec. 31, 2021	$ 1	$ 1	$ 684		$ 43	$ 400		$ 106,049	$ 264,925	29,769,450	(956,394)
Ending balance, shares at Dec. 31, 2021	688	9,938	6,838,889		425,000	4,000,000	0	1,060,492,608	25,500,000
Loss for the period												(7,367,583)
Common stock for comp									$ 6,470,634		6,470,634
Common stock for comp , shares									402,132,500
Common stock for debt conversion
Preferred stock for compensation
Subscriptions receivable
Issuance of issuable shares								$ 2,000	$ (200,000)	198,000
Shares sold for cash , shares								20,000,000	(20,000,000)
Common stock for services
Loss for the period											(7,367,583)
As at March 31, 2022 at Mar. 31, 2022	$ 1	$ 1	$ 684		$ 43	$ 400		$ 108,049	$ 6,535,559	$ 29,967,450	$ (1,853,343)	$ (1,853,344)
Ending balance, shares at Mar. 31, 2022	688	9,938	6,838,889		425,000	4,000,000	0	1,080,492,608	407,632,500

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flow from operating activities
Net loss	$ (12,091,303)	$ (2,532,035)
Adjustment for non-cash charges and other items:
Depreciation and amortization	5,849	0
Common stock issued for services	0	4,899
Stock compensation expense	9,610,554	1,829,150
Loss on change in fair value of derivative	213,053	31,940
Gain on accounts payable extinguishment	(156,616)	0
Gain on settlement of convertible notes payable	(96,145)	0
Amortization of debt discount	0	4,167
Total adjustments	(2,514,608)	(661,879)
Changes in working capital
Decrease / (increase) in accounts receivable	25,694	11,746
Decrease / (increase) in prepaid inventory	0	59,898
Decrease / (increase) in prepaid expenses	16,485	0
(Decrease) / increase in trade and other payables	(67,992)	(53,402)
(Decrease) / increase in accrued expenses	99,393	264,536
(Decrease) / increase in accrued expenses - related party	(204,121)
(Decrease) / increase in deferred revenue	(25,992)	(63,790)
Total changes in working capital	(156,533)	218,988
Cash flow used in operating activities	(2,671,141)	(442,891)
Cash flow provided by investing activities
Decrease / (increase) in property, plant & equipment	(50,000)	0
Acquisition of company	0	(400)
Cash flow provided by financing activities	(50,000)	(400)
Cash flow provided by financing activities
Proceeds from note payable	25,000	550,000
Proceeds from issuance of stock for cash	3,300,000	0
Repayments of note payable	(825,864)	(80,166)
Payments to related parties	(55,452)	(14,968)
Cash flow from financing activities	2,443,684	454,866
Increase in cash and cash equivalents	(277,457)	11,575
Cash and cash equivalents at the beginning of the period	847,430	0
Cash and cash equivalents at end of the period	569,973	11,575
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversions of notes and accrued interest	269,954	0
Interest	0	0
Taxes	$ 0	$ 0

Nature and Continuance of Opera

Nature and Continuance of Operations	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature and Continuance of Operations	Note 1 – Nature and Continuance of Operations Wearable Health Solutions Inc. (the Company) was incorporated as Medical Alarm Concepts Holding, Inc., on June 4, 2008, under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”). On May 26, 2016, the Company filed an Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable Health Solutions Inc.” Wearable Health Solutions provides mobile health (mHealth) products and services to be used by customers in case of an emergency. As a provider of personal emergency response devices, we provide innovative wearable healthcare products, tracking services, and turn-key solutions that enable our users to be proactive with their health, as well as safe and protected. Our flagship products are the iHelp devices, the 3G and the next generation iHelp MAX™ - personal emergency alarms that are used to summon help in the event of an emergency at home. Basis of presentation The accompanying interim condensed consolidated financial statements are unaudited, but in the opinion of management of Wearable Health Solutions, Inc. (the Company), contain all adjustments, which include normal recurring adjustments, necessary to present fairly the financial position at March 31, 2022 and the results of operations and cash flows for the three and nine months ended March 31, 2022. The balance sheet as of June 30, 2021, is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements that have been prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, although management of the Company believes that the disclosures contained in these financial statements are adequate to make the information presented therein not misleading. For further information, refer to the financial statements and the notes thereto included in the Company’s Annual Report on the Form 10 for the fiscal year ended June 30, 2021, that was filed with the Securities and Exchange Commission on November 19, 2021, with its final amendment on March 23, 2022. The results of operations for the three and nine months ended March 31, 2022, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending June 30, 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Principles of Consolidation Use of Estimates Cash and Cash Equivalents Accounts Receivable 0 25,694 23,705 23,705 Software Development for internal use 50,000 5 Concentration of Credit Risk Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical- or age-related conditions. The Company recognizes revenue for services over time as the performance obligations are met and for product sales at a point in time when the performance obligations are met. For hardware sales, the Company recognizes revenues when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues when the service is provided. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues and records the balance of revenues as they become current. Schedule of revenues 3 months ended March 31, 9 months ended March 31, REVENUES 2022 2021 2022 2021 Hardware revenue $ 5,659 $ 90,412 $ 82,644 $ 296,426 Service revenue 207,323 192,909 736,957 739,345 TOTAL REVENUES $ 212,982 $ 283,321 $ 819,601 $ 1,035,771 The following table discloses changes in contract liabilities for the three and nine months ended March 31, 2022. Schedule of unearned revenue 3 months ended March 31, 2022 9 months ended March 31, 2022 Balance at beginning of period – December 31, 2021 and June 30, 2021 $ 95,015 $ 108,298 Contract liabilities 48,510 168,823 Recognition of contract liabilities (61,219 ) (194,815 ) Balance at the end of the period - March 31, 2022 $ 82,306 $ 82,306 Contract liabilities at March 31, 2022 and June 30, 2021 was $ 82,306 108,298 Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2021, 2020, and 2019 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed. Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards. Research and Development 43,472 149,000 0 0 Basic and Diluted Loss per Common Share Schedule of anti-dilutive shares Basis of conversion Dilution March 31, 2022 June 30, 2021 Series A Convertible 688 shares outstanding 1 share A: 2 shares 1,376 1,376 Series B Convertible 9,938 shares outstanding 1 share B: 2 shares 19,876 19,876 Series C Convertible 6,838,889 and 138,886 shares outstanding as of March 31, 2022 and June 30, 2021, respectively 1 share C: 10 shares 68,388,890 1,388,860 Series C Convertible -0- and 6,700,003 shares to be issued as of March 31, 2022 and June 30, 2021, respectively 1 share C: 10 shares – 67,000,030 Series D Convertible 425,000 shares outstanding 1 share D: 100 shares 42,500,000 42,500,000 Series E Convertible 4,000,000 and 1,900,000 shares outstanding as of March 31, 2022 and June 30, 2021, respectively 1 share E: 100 shares 400,000,000 190,000,000 Series E Convertible Shares to be issued -0- and 100,000 Series E shares to be issued as of March 31, 2022 and June 30, 2021, respectively 1 share E: 100 shares – 10,000,000 510,910,142 300,910,142 Because the Company incurred losses for the past two years, the basic and diluted share bases will be presented as the same. For the three and nine months ended March 31, 2022 and 2021, the Company incurred losses of ($0.01) and ($0.00) per basic share and diluted share, respectively. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. Earlier application is permitted. The Company evaluated the impact on the financial statements and implemented the provisions of ASU 2016-02 for the annual financial statements for the year ended June 30, 2019. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Going Concern

Going Concern	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The accompanying consolidated financial statements for the three and nine months ended March 31, 2022 and 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As at March 31, 2022 and June 30, 2021, the Company has shown losses for the last 2 years and has an accumulated deficit of ($ 38,465,530 26,374,227 These factors raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Inventory, Prepaid Inventory, a

Inventory, Prepaid Inventory, and Prepaid Expenses	9 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory, Prepaid Inventory, and Prepaid Expenses	Note 4 – Inventory, Prepaid Inventory, and Prepaid Expenses The Company maintains some inventories in house and purchases some of its inventory overseas. Inventories, except for stock in transit, are stated at lower of cost and net realizable value. Stock in transit is valued at cost comprising invoice value plus other charges thereon. Net realizable value is the estimated selling price in ordinary course of business less estimated costs of completion and selling expenses. The quantity of inventory may vary from time to time depending on the delivery schedule of overseas shipments. As of March 31, 2022 and June 30, 2021, the Company had $- 0 0 16,197 22,682 The Company recorded prepaid public relations and investor relations (PR/IR) services of $- 0 10,000 As of March 31, 2022 and June 30, 2021, the Company had $- 0 10,000

Property, Plant, and Equipment

Property, Plant, and Equipment	9 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant, and Equipment	Note 5 – Property, Plant, and Equipment The Company has $20,000 in furnishings, $19,689 in office computers and equipment, and capitalized software development costs of $45,900 which are fully depreciated. On August 30, 2021, the Company purchased its dealer portal for $50,000 for internal use, amortized over 60 months. As of March 31, 2022 and June 30, 2021, the Company recorded $ 44,151 0 Schedule of property, plant and equipment March 31, 2022 June 30, 2021 Furniture $ 20,000 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer Portal 50,000 – Property, plant, and equipment 135,589 85,589 Less accumulated depreciation – portal (5,849 ) – Less accumulated depreciation (85,589 ) (85,589 ) Net property, plant, and equipment $ 44,151 $ - 0

Accounts payable and accrued ex

Accounts payable and accrued expenses and liabilities	9 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accounts payable and accrued expenses and liabilities	Note 6 – Accounts payable and accrued expenses and liabilities The Company recorded Accounts Payable of $ 107,268 331,876 Accrued expenses are expenses that have been incurred but not yet paid, mainly include legal fees, audit fees and other professional fees as well as interests accrued in connection with notes payable and credit line. The Company recorded $ 377,360 296,920 3a10 filing On August 17, 2020, the Wearable Health Solutions, Inc., (the “Company”) entered into a settlement agreement and stipulation (“Settlement Agreement”) with Trillium Partners LP (“Trillium”) in connection with the settlement of $ 310,494 In October 2020, the Company issued 48,989,000 60 48,989,000

Notes Payable and Note payable-

Notes Payable and Note payable-other	9 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes Payable and Note payable-other	Note 7 – Notes Payable and Note payable-other Short term bridge loan - COHEN On July 31, 2020, the Company secured a $ 500,000 12 12 At June 30, 2021, the Company recorded short term note payable of $ 500,000 55,027 On August 19, 2021, the Company repaid $ 300,000 100,000 At March 31, 2022, the Company recorded short term note payable of $ 100,000 18,649 Note payable – stock purchases under Reg A In March 2021 and June 2021, the Company accepted loans of $ 115,000 20,000 5 In October 2021, the Company accepted a loan of $ 5,000 140,000 115,000 8,736 1,594 As of March 31, 2022 and June 30, 2021, the Company has outstanding $ 430,380 853,244 Note Payable – Other In November 2016, the Company secured a $ 50,000 4 1,000,000 4 As of March 31, 2022 and June 30, 2021, the Company expensed $ 1,500 2,000 10,983 9,283 Convertible note payable – other On March 1, 2016 and March 3, 2016, the Company closed a private placement and received an aggregate of $ 612,500 660,000 13,750 61,250 As of March 31, 2022 and June 30, 2021, the Company reported $ 673,750 673,750 On July 22, 2021, the Company filed suit for damages resulting from the related party. On November 4, 2021, Benza Pharma LLC filed a countersuit. To date, there has been no resolution or settlement. The loans are recognized on the financials with no discount. Convertible Note: Leonite Capital, LLC On November 19, 2019, the Company, together with Hypersoft Ventures (collectively, the “Borrower”), received $ 135,000 150,000 15,000 2,700,000 The Company has determined that the conversion feature embedded in the Leonite Convertible Note constitutes a derivative and has been bifurcated from the Leonite Convertible Note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt, on the accompanying balance sheet, and revalued to fair market value at each reporting period. The initial issuance yielded a derivative liability of $ 94,225 Significant assumptions used in calculating fair value of conversion feature of Leonite Convertible Note at issuance date are as follows: Schedule of fair value of conversion feature Expected Expected Risk-free Expected Exercise Common stock 0.00 809.71 0.0154 0.75 $ 0.02 $ 0.01300 On June 4, 2021, the Company and Leonite renegotiated the convertible note for two years, face value of $ 260,000 On July 29, 2021, Leonite converted $ 42,750 2,250 15,000,000 44,475 2,250 10,269,253 On October 6, 2021, Leonite converted $ 57,952 2,250 13,231,209 125,000 2,250 27,917,969 96,145 Schedule of extinguishment of debt Balance at June 30, 2021 $ 260,000 Accrued interest 9,954 Leonite Convertible Note converted (269,954 ) Total 0 Less: debt discount (0 ) Balance at March 31, 2022 $ 0 The resulting derivative valuation is calculated as follows: Schedule of derivative liabilities at fair value Derivative as of June 30, 2021 $ 281,845 Change in fair value 238,155 520,000 Write off due to conversions (176,800 ) Derivative value as of September 30, 2021 $ 343,200 Change in fair value (25,102 ) 318,098 Write off due to conversion (221,953 ) 96,145 Gain on extinguishment (96,145 ) Derivative as of March 31, 2022 $ – Significant assumptions used in calculating fair value of conversion feature of Leonite Convertible Note as of March 31, 2022 are as follows: Schedule of fair value of conversion features Expected Expected Risk-free Expected term Exercise Common stock 0.00 269.75 0.0007 1.9288 $ 0.00550 $ 0.01 As of March 31, 2022 and June 30, 2021, the Company has recorded $- 0 260,000 Credit line – MediPendant New York Inc. On September 30, 2014, our subsidiary entered into a line of credit with Medi Pendant New York, Inc. (“MNY”), which is partially owned by a principal of its subsidiary. Under the line of credit agreement, the Company will be able to borrow up to $ 500,000 6.5 September 30, 2017 500,000 200,000 28,000 As of March 31, 2022 and June 30, 2021, the Company has recorded $ 397,500 397,500

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Deficit	Note 10 – Stockholders’ Deficit Capital Stock The Company is currently authorized to issue 3,000,000,000 0.0001 0.0001 For the nine months ended March 31, 2021, the Company issued 200,000,000 1,140,000 150,000 1,500 525,000 3,861 For the nine months ended March 31, 2022, the Company issued 7,000,000 75,000 .0107 5,000,000 60,000 20,000,000 402,132,500 6,470,634 As of March 31, 2022 and June 30, 2021, the Company has 1,080,492,608 and 697,074,199 shares of common stock issued and outstanding and 407,632,500 and 20,050,000 issuable common stock shares, respectively. Offering pursuant to Regulation A On September 11, 2020, the Company filed a 1-A offering statement with the Securities and Exchange commission, offering up to 500,000,000 shares of common stock at $.01 to raise up to $5,000,000. The offering was amended on October 14, 2020 and can be viewed on the SEC website, www.sec.gov. Preferred Stock Series A Convertible Preferred Stock 100,000 0.0001 Series B Convertible Preferred Stock 62,500 0.0001 Series C Convertible Preferred Stock 6,944,445 0.0001 Series D Convertible Preferred Stock: The Company is currently authorized to issue, 500,000 0.0001 Series E Convertible Preferred Stock: The Company is currently authorized to issue 4,000,000 0.0001 During the nine months ended March 31, 2021, the Company issued 6,700,003 375,000 .056 4,000,000 400 .0001 1,900,000 1,223,000 .64 During the nine months ended March 31, 2022, the Company issued 1,000,000 3,000,000 1.50 50,000 57,000 .57 As of March 31, 2022 and June 30, 2021, the Company had 688 9,938 6,838,889 425,000 4,000,000 All shares were valued at the stock price on the day of transaction or conversion.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions Note payable – BOAPIN purchase In June 2019, the Company purchased the BOAPIN portal, including all software, licensing, and ownership rights from Hypersoft Ventures, Inc., a related party, for $425,670, which includes six million seven hundred thousand (6,700,003) shares of Series C Convertible Preferred stock and a note for $425,000, bearing twelve percent (12%) interest with no prepayment or delinquency clauses. On October 28, 2021, the Company repaid $ 105,000 150,000 During the quarter ended March 31, 2022, Company repaid $ 123,000 1,410 As of March 31, 2022 and June 30, 2021, the Company has recorded Note payable-BOAPIN of $ 47,000 425,000 44,315 28,225 Accrued expenses and due to related party From time to time, related parties loaned the company working capital for day-to-day operations, respectively. These are short-term loans which bear no interest, and the Company expects to repay these loans within the coming year. In addition, salary accruals owed to the officers of the Company have been included in the Due to related party line item. As of March 31, 2022 and June 30, 2021, the Company owes $ 320,101 579,673

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 12 – Commitments and contingencies Commitments and Contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. The Company is currently involved in the below litigation matters. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. 1) Wearable Health Solutions, In. v. Barry Honig, GRQ Consultants Inc., Benza Pharma LLC and John Does 1-10, Supreme Court of the State of New York County of New York, July 22, 2021. Company is disputing the validity of Notes from 3/2016 and seeking damages, reparations, and related costs. 2) GRQ Consultants, Inc. v. Wearable Health Solutions, Inc., Supreme Court of the State of New York, County of New York, August 26, 2021, Parties are seeking summary judgment of $50,000 plus accrued interest in response to lawsuit by Company regarding $50,000 loan from 11/2016. 3) Benza Pharma LLC, Sandor Capital, LP, and John Lemak v. Wearable Health Solutions, Inc., District Court, Clark County, Nevada, Parties are seeking summary judgment of $3,000,000 plus accrued interest in regards to convertible notes payable from March, 2016. 4) Medical Alarm Concepts LLC v. MCA Cure, LLC, Superior Court of New Jersey, Law Division, Morris County. Company is seeking return of payments for non-performance plus attorney fees and court costs. A settlement was reached between the parties whereby MCA Cure will pay an initial $10,000 and $6,500 each month until debt is satisfied in 2023 (See Note 14).

Office lease

Office lease	9 Months Ended
	Mar. 31, 2022
Office Lease
Office lease	Note 13 – Office lease The Company maintains its corporate offices in Newport Beach, California, on a month-to-month basis. The subsidiary maintains a warehouse office in Pennsylvania to facilitate inventory arrival and product shipment. The 3-year lease at $1,100 per month expired on September 30, 2021. The lease has been renewed for 12 months at $1,300 per month beginning October 1, 2021. Expenditures for the nine months ending March 31, 2022 and 2021 are as follows: Schedule lease cost 2022 2021 Rent expense $ 12,555 $ 11,418

Other income - settlement

Other income - settlement	9 Months Ended
	Mar. 31, 2022
Other Income and Expenses [Abstract]
Other income - settlement	Note 14 – Other income - settlement Settlement In 2019, the Company engaged MCA Cure to negotiate settlements with two note holders, and paid MCA Cure a total of $ 97,625 105,125 As of March 31, 2022 and 2021, the Company has recorded $ 23,000 0

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events Management is reporting the passing of its founder Ronald Adams. The company has shared the news corporately with its network of 200 domestic and international dealers and vendors. Mr. Adams responsibilities have been assumed by Marc Cayle as Vice President of Innovation and Development for the company. Mr. Cayle has over 18 years of experience in the Seniors Health Care and Personal Emergency Response Systems (PERS) sectors. He also founded several Seniors Care related companies specific to the Home Health Care industry. The company has updated its websites at; wearablehealthsolutions.com; ihelpalarm.com; 1800medalert.com and wearablehealthsolutions.com/investor-relations reflecting corporate, product, DTC and investor relations references. Common stock In April 2022, the Company issued 402,650,000 shares of common stock to its management for compensation and bonuses, previously accrued, 10,000,000 shares of restricted common stock to an independent consultant, and cancelled 28,000,000 shares. As of the date of this filing, the Company has 1,465,143,608 shares issued and outstanding.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable 0 25,694 23,705 23,705
Software Development for internal use	Software Development for internal use 50,000 5
Concentration of Credit Risk	Concentration of Credit Risk
Recognition of Revenues	Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical- or age-related conditions. The Company recognizes revenue for services over time as the performance obligations are met and for product sales at a point in time when the performance obligations are met. For hardware sales, the Company recognizes revenues when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues when the service is provided. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues and records the balance of revenues as they become current. Schedule of revenues 3 months ended March 31, 9 months ended March 31, REVENUES 2022 2021 2022 2021 Hardware revenue $ 5,659 $ 90,412 $ 82,644 $ 296,426 Service revenue 207,323 192,909 736,957 739,345 TOTAL REVENUES $ 212,982 $ 283,321 $ 819,601 $ 1,035,771 The following table discloses changes in contract liabilities for the three and nine months ended March 31, 2022. Schedule of unearned revenue 3 months ended March 31, 2022 9 months ended March 31, 2022 Balance at beginning of period – December 31, 2021 and June 30, 2021 $ 95,015 $ 108,298 Contract liabilities 48,510 168,823 Recognition of contract liabilities (61,219 ) (194,815 ) Balance at the end of the period - March 31, 2022 $ 82,306 $ 82,306 Contract liabilities at March 31, 2022 and June 30, 2021 was $ 82,306 108,298
Deferred Taxes	Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2021, 2020, and 2019 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed.
Fair value of financial instruments	Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards.
Research and Development	Research and Development 43,472 149,000 0 0
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share Schedule of anti-dilutive shares Basis of conversion Dilution March 31, 2022 June 30, 2021 Series A Convertible 688 shares outstanding 1 share A: 2 shares 1,376 1,376 Series B Convertible 9,938 shares outstanding 1 share B: 2 shares 19,876 19,876 Series C Convertible 6,838,889 and 138,886 shares outstanding as of March 31, 2022 and June 30, 2021, respectively 1 share C: 10 shares 68,388,890 1,388,860 Series C Convertible -0- and 6,700,003 shares to be issued as of March 31, 2022 and June 30, 2021, respectively 1 share C: 10 shares – 67,000,030 Series D Convertible 425,000 shares outstanding 1 share D: 100 shares 42,500,000 42,500,000 Series E Convertible 4,000,000 and 1,900,000 shares outstanding as of March 31, 2022 and June 30, 2021, respectively 1 share E: 100 shares 400,000,000 190,000,000 Series E Convertible Shares to be issued -0- and 100,000 Series E shares to be issued as of March 31, 2022 and June 30, 2021, respectively 1 share E: 100 shares – 10,000,000 510,910,142 300,910,142 Because the Company incurred losses for the past two years, the basic and diluted share bases will be presented as the same. For the three and nine months ended March 31, 2022 and 2021, the Company incurred losses of ($0.01) and ($0.00) per basic share and diluted share, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. Earlier application is permitted. The Company evaluated the impact on the financial statements and implemented the provisions of ASU 2016-02 for the annual financial statements for the year ended June 30, 2019. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of revenues	Schedule of revenues 3 months ended March 31, 9 months ended March 31, REVENUES 2022 2021 2022 2021 Hardware revenue $ 5,659 $ 90,412 $ 82,644 $ 296,426 Service revenue 207,323 192,909 736,957 739,345 TOTAL REVENUES $ 212,982 $ 283,321 $ 819,601 $ 1,035,771
Schedule of unearned revenue	Schedule of unearned revenue 3 months ended March 31, 2022 9 months ended March 31, 2022 Balance at beginning of period – December 31, 2021 and June 30, 2021 $ 95,015 $ 108,298 Contract liabilities 48,510 168,823 Recognition of contract liabilities (61,219 ) (194,815 ) Balance at the end of the period - March 31, 2022 $ 82,306 $ 82,306
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares Basis of conversion Dilution March 31, 2022 June 30, 2021 Series A Convertible 688 shares outstanding 1 share A: 2 shares 1,376 1,376 Series B Convertible 9,938 shares outstanding 1 share B: 2 shares 19,876 19,876 Series C Convertible 6,838,889 and 138,886 shares outstanding as of March 31, 2022 and June 30, 2021, respectively 1 share C: 10 shares 68,388,890 1,388,860 Series C Convertible -0- and 6,700,003 shares to be issued as of March 31, 2022 and June 30, 2021, respectively 1 share C: 10 shares – 67,000,030 Series D Convertible 425,000 shares outstanding 1 share D: 100 shares 42,500,000 42,500,000 Series E Convertible 4,000,000 and 1,900,000 shares outstanding as of March 31, 2022 and June 30, 2021, respectively 1 share E: 100 shares 400,000,000 190,000,000 Series E Convertible Shares to be issued -0- and 100,000 Series E shares to be issued as of March 31, 2022 and June 30, 2021, respectively 1 share E: 100 shares – 10,000,000 510,910,142 300,910,142

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	9 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Schedule of property, plant and equipment March 31, 2022 June 30, 2021 Furniture $ 20,000 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer Portal 50,000 – Property, plant, and equipment 135,589 85,589 Less accumulated depreciation – portal (5,849 ) – Less accumulated depreciation (85,589 ) (85,589 ) Net property, plant, and equipment $ 44,151 $ - 0

Notes Payable and Note payabl_2

Notes Payable and Note payable-other (Tables)	9 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of fair value of conversion feature	Schedule of fair value of conversion feature Expected Expected Risk-free Expected Exercise Common stock 0.00 809.71 0.0154 0.75 $ 0.02 $ 0.01300
Schedule of extinguishment of debt	Schedule of extinguishment of debt Balance at June 30, 2021 $ 260,000 Accrued interest 9,954 Leonite Convertible Note converted (269,954 ) Total 0 Less: debt discount (0 ) Balance at March 31, 2022 $ 0
Schedule of derivative liabilities at fair value	Schedule of derivative liabilities at fair value Derivative as of June 30, 2021 $ 281,845 Change in fair value 238,155 520,000 Write off due to conversions (176,800 ) Derivative value as of September 30, 2021 $ 343,200 Change in fair value (25,102 ) 318,098 Write off due to conversion (221,953 ) 96,145 Gain on extinguishment (96,145 ) Derivative as of March 31, 2022 $ –
Schedule of fair value of conversion features	Schedule of fair value of conversion features Expected Expected Risk-free Expected term Exercise Common stock 0.00 269.75 0.0007 1.9288 $ 0.00550 $ 0.01

Office lease (Tables)

Office lease (Tables)	9 Months Ended
	Mar. 31, 2022
Office Lease
Schedule lease cost	Schedule lease cost 2022 2021 Rent expense $ 12,555 $ 11,418

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Schedule of Revenues) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Product Information [Line Items]
Revenues	$ 212,982	$ 283,321	$ 819,601	$ 1,035,771
Hardware Revenue [Member]
Product Information [Line Items]
Revenues	5,659	90,412	82,644	296,426
Service Revenue [Member]
Product Information [Line Items]
Revenues	$ 207,323	$ 192,909	$ 736,957	$ 739,345

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Schedule of Unearned Revenue) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2022
Accounting Policies [Abstract]
Contract with Customer, Liability, Current	$ 95,015	$ 108,298
Deferred Revenue, Additions	48,510	168,823
Deferred Revenue, Revenue Recognized	(61,219)	(194,815)
Contract with Customer, Liability, Current	$ 82,306	$ 82,306

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details - Antidilutive information) - shares	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Jun. 30, 2021
AntiDilutive Shares		510,910,142	300,910,142
Series A Preferred Stock [Member]
AntiDilutive Shares		1,376	1,376
Series B Preferred Stock [Member]
AntiDilutive Shares		19,876	19,876
Series C Preferred Stock [Member]
AntiDilutive Shares		68,388,890	1,388,860
Series C Preferred Stock 1 [Member]
AntiDilutive Shares		0	67,000,030
Series D Preferred Stock [Member]
AntiDilutive Shares		42,500,000	42,500,000
Series E Preferred Stock [Member]
AntiDilutive Shares		400,000,000	190,000,000
Series E Preferred Stock To Be Issued [Member]
AntiDilutive Shares		0	10,000,000
Series A Convertible Stock [Member]
Basis of conversion	688 shares outstanding
Dilution	1 share A: 2 shares
Series B Convertible Stock [Member]
Basis of conversion	9,938 shares outstanding
Dilution	1 share B: 2 shares
Series C Convertible Stock [Member]
Basis of conversion	6,838,889 and 138,886 shares outstanding as of March 31, 2022 and June 30, 2021, respectively
Dilution	1 share C: 10 shares
Series C Convertible Stock 1 [Member]
Basis of conversion	-0- and 6,700,003 shares to be issued as of March 31, 2022 and June 30, 2021, respectively
Dilution	1 share C: 10 shares
Series D Convertible Stock [Member]
Basis of conversion	425,000 shares outstanding
Dilution	1 share D: 100 shares
Series E Convertible Stock [Member]
Basis of conversion	4,000,000 and 1,900,000 shares outstanding as of March 31, 2022 and June 30, 2021, respectively
Dilution	1 share E: 100 shares
Series E Convertible Shares To Be Issued [Member]
Basis of conversion	-0- and 100,000 Series E shares to be issued as of March 31, 2022 and June 30, 2021, respectively
Dilution	1 share E: 100 shares

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 30, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Accounting Policies [Abstract]
Accounts receivable, net		$ 0		$ 0		$ 25,694
Allowance for doubtful accounts		23,705		23,705		23,705
Purchase of dealer portal	$ 50,000
Depreciated years	5 years
Deferred revenue		82,306		82,306		$ 108,298
Research and Development Expense		$ 43,472	$ 0	$ 149,000	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 38,465,530	$ 26,374,227

Inventory, Prepaid Inventory,_2

Inventory, Prepaid Inventory, and Prepaid Expenses (Details Narrative) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Inventory, net	$ 0	$ 0
Prepaid inventories	16,197	22,682
Prepaid inventory	0	10,000
Public Relations And Investor Relations [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid inventory	$ 0	$ 10,000

Property, plant and equipment (

Property, plant and equipment (Details) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 135,589	$ 85,589
[custom:AccumulatedDepreciationDepletionPortalAndAmortizationPropertyPlantAndEquipments-0]	(5,849)	0
Less accumulated depreciation	(85,589)	(85,589)
Net property, plant, and equipment	44,151	0
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	20,000	20,000
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	19,689	19,689
Software Development [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	45,900	45,900
Dealer Portal [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 50,000	$ 0

Property, Plant, and Equipmen_2

Property, Plant, and Equipment (Details Narrative) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Other, Net	$ 44,151	$ 0

Accounts payable and accrued _2

Accounts payable and accrued expenses and liabilities (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Accounts payable	$ 107,268	$ 331,876
Accrued liabilities	377,360	$ 296,920
Trillium Partners L P [Member]
Defined Benefit Plan Disclosure [Line Items]
Company owed to certain of creditors	310,494
W H S I [Member]
Defined Benefit Plan Disclosure [Line Items]
Common stock issued	$ 48,989,000
Common stock percentage price	60.00%
Treasury shares returned	$ 48,989,000

Notes Payable and Note Payable

Notes Payable and Note Payable - Other (Details - Fair Value Conversion Feature) - Leonite [Member]	9 Months Ended
	Mar. 31, 2022$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected Dividends	0.00%
Expected Volatility	809.71%
Risk-free rate of interest	0.0154%
Expected term (year)	9 months
Exercise conversion price	$ 0.02
Common stock price per share	$ 0.01300

Notes Payable and Note Payabl_3

Notes Payable and Note Payable - Other (Details - Schedule of Extinguishment of Debt) - Leonite Capital [Member]	9 Months Ended
	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
Convertible debt, beginning balance	$ 260,000
Convertible debt issued	9,954
Convertible debt converted	(269,954)
Convertible debt, beginning balance	0
Debt discount	0
Convertible debt, ending balance	$ 0

Notes Payable and Note Payabl_4

Notes Payable and Note Payable - Other (Details - Derivative Liabilities) - USD ($)	3 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Derivative liabilities, Beginning		$ 281,845
Change in fair value	$ (25,102)	238,155
Total Fair Value Derivative Liabilities	318,098	520,000
Write off due to conversions	(221,953)	(176,800)
Total fair value	96,145
Gain on extinguishment	(96,145)
Derivative liabilities, Ending	$ 0	$ 343,200

Notes Payable and Note Payabl_5

Notes Payable and Note Payable - Other (Details 4) - Leonite 1 [Member]	9 Months Ended
	Mar. 31, 2022$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected Dividends	0.00%
Expected Volatility	269.75%
Risk-free rate of interest	0.0007%
Expected term (year)	1 year 11 months 4 days
Exercise conversion price	$ 0.00550
Common stock price per share	$ 0.01

Notes Payable and Note payabl_6

Notes Payable and Note payable-other (Details Narrative) - USD ($)	Oct. 26, 2021	Oct. 06, 2021	Aug. 27, 2021	Jul. 29, 2021	Nov. 19, 2019	Jan. 31, 2022	Nov. 30, 2021	Jul. 31, 2021	Jul. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Oct. 31, 2021	Aug. 19, 2021	Jun. 04, 2021
Short-Term Debt [Line Items]
Short term notes payable										$ 100,000		$ 100,000		$ 500,000
Interest and accrued interest liability												18,649		55,027
Principle amount repaid																$ 300,000
Repayment of debt							$ 100,000
Loans payable															$ 5,000
Notes payable for stock purchases										140,000		140,000		115,000
Notes payable, other										8,736		8,736		1,594
Notes payable										430,380		430,380		853,244
Notes payable related parties										$ 47,000		$ 47,000		425,000
Interest rate										4.00%		4.00%
Interest fees										$ 1,500				2,000
Accrued interest payable										10,983				9,283
Unsecured convertible notes												$ 269,954	$ 0
Gain (Loss) on Extinguishment of Debt												96,145
Borrowed amount										500,000		$ 500,000
Maturity date												Sep. 30, 2017
Increased amount												$ 500,000
Issuance of shares						20,000,000
Line of credit balance										397,500		$ 397,500		397,500
Medi Pendant New York Inc [Member]
Short-Term Debt [Line Items]
Rate of interest												6.50%
Issuance of shares												200,000
Issuance of shares value												$ 28,000
Leonite [Member]
Short-Term Debt [Line Items]
Convertible notes										0		0		260,000
Convertible note face value																	$ 260,000
Debt Instrument, Convertible, Liquidation Preference, Value	$ 125,000	$ 57,952	$ 44,475	$ 42,750
Debt Instrument, Fee Amount	$ 2,250	$ 2,250	$ 2,250	$ 2,250
Debt Conversion, Converted Instrument, Shares Issued	27,917,969	13,231,209	10,269,253	15,000,000
Gain (Loss) on Extinguishment of Debt												96,145
Leonite Convertible Note [Member]
Short-Term Debt [Line Items]
Company recieved amount					$ 135,000
Convertible note face value					150,000
Original Issue Discount					$ 15,000
[custom:StockIssuedForDebtShares]					2,700,000
Derivative Liability					$ 94,225
Private Placement [Member]
Short-Term Debt [Line Items]
Aggregate amount										612,500		612,500
Original issue discount										61,250
Convertible notes										$ 673,750		673,750		673,750
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Interest rate										4.00%
Notes payable related parties										$ 50,000		$ 50,000
Acquisition of convertible notes payable										1,000,000
Two Unaffiliated Investors [Member]
Short-Term Debt [Line Items]
Loans accepted								$ 20,000			$ 115,000		$ 115,000	$ 115,000
Notes payable interest rate								5.00%
B E N Z A [Member] | Private Placement [Member]
Short-Term Debt [Line Items]
Unsecured convertible notes										660,000
B 2 C F [Member] | Private Placement [Member]
Short-Term Debt [Line Items]
Unsecured convertible notes										$ 13,750
C O H E N [Member]
Short-Term Debt [Line Items]
Short term bridge loan									$ 500,000
Interest rate									12.00%
Accrue interest									12.00%

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Jan. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Class of Stock [Line Items]
Common stock, shares authorized		3,000,000,000		3,000,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Preferred stock, par value		$ 0.0001		$ 0.0001
Stock issued for services, shares	20,000,000
Accured shares		5,000,000	525,000
Compensation, value			$ 3,861
Shares issued		7,000,000
Contractual bonuses		$ 75,000
Contractual bonus price per share		$ 0.0107
Bonus paid amount		$ 60,000
Employee compensation, shares	402,132,500
Employee compensation, value	$ 6,470,634
Preferred stock, shares authorized		25,000,000		25,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		100,000		100,000
Preferred stock, shares issued		688		688
Preferred stock, shares outstanding		688		688
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		62,500		62,500
Preferred stock, shares issued		9,938		9,938
Preferred stock, shares outstanding		9,938		9,938
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.0001		$ 0.0001
Shares issued			6,700,003
Preferred stock, shares authorized		6,944,445		6,944,445
Issued amount			$ 375,000
Issued price			$ 0.056
Preferred stock, shares issued		6,838,889		138,886
Preferred stock, shares outstanding		6,838,889		138,886
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, shares authorized		500,000		500,000
Preferred stock, shares issued		425,000		425,000
Preferred stock, shares outstanding		425,000		425,000
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.0001		$ 0.0001
Shares issued		1,000,000	4,000,000
Preferred stock, shares authorized		4,000,000		4,000,000
Issued amount		$ 3,000,000	$ 400
Issued price		$ 1.50	$ 0.0001
Preferred stock, shares issued		4,000,000		1,900,000
Preferred stock, shares outstanding		4,000,000		1,900,000
Series E Preferred Stock [Member] | Two Officer [Member]
Class of Stock [Line Items]
Shares issued			1,900,000
Issued amount		$ 57,000	$ 1,223,000
Issued price		$ 0.57	$ 0.64
Preferred stock, shares issued		50,000
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued		4,000,000
Preferred stock, shares outstanding		4,000,000
New Owner [Member]
Class of Stock [Line Items]
Stock issued for services, shares			200,000,000
Stock issued for services, value			$ 1,140,000
Accrued, shares			150,000
Accrued, value			$ 1,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 01, 2021	Oct. 28, 2021	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Related Party Transaction [Line Items]
Repayment related party debt				$ 55,452	$ 14,968
Accrued interest			$ 44,315	44,315		$ 28,225
Related party payables			320,101	320,101		579,673
Boapin [Member]
Related Party Transaction [Line Items]
Repayment related party debt	$ 150,000	$ 105,000	123,000
Interest Expense, Debt			1,410
Note payable			$ 47,000	$ 47,000		$ 425,000

Office lease (Details)

Office lease (Details) - USD ($)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Office Lease
Rent expense	$ 12,555	$ 11,418

Other income - settlement (Deta

Other income - settlement (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2019	Feb. 28, 2022
Other Income and Expenses [Abstract]
Payment for contract services			$ 97,625
Attorney costs				$ 105,125
Settlement income	$ 23,000	$ 0